Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To achieve appropriate exposure for an anterior neck surgery (for example an Anterior Cervical Discectomy and Fusion or ACDF), patients are positioned supine with their neck extended. Due to being in this position, patients frequently complain of posterior neck stiffness and pain postoperatively in addition to the anterior incisional pain. This posterior cervical pain can be classified as myofascial pain.
Cervical myofascial pain is thought to be the result of overuse or trauma to the supporting muscles of the neck and shoulders. Trigger point injections are one of the methods used to treat myofascial pain. The trigger point injection procedure is where a physician (typically an anesthesiologist) performs an exam of the patient neck and upper back and finds areas of point tenderness. The physician will then inject a small amount of numbing medication (such as bupivacaine) into the muscle or tissue in that area.
Trigger point injections have been shown to be superior to botox injections or dry needling, and equivalent to physical therapy. However, these studies were performed on patients with chronic neck pain. There are no studies evaluating the effectiveness of trigger point injections on post anterior cervical surgery patients.
At our institution, trigger point injections with local anesthetic are used as part of a multimodal pain control regimen for post-anterior cervical surgery patients. Our hypothesis is if the addition of trigger point injections to standard of care multi-modal post-operative pain control will decrease patients' myofascial pain, and thereby decrease the amount of narcotic pain medication used.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lidocaine skin wheal | Sham Comparator | They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. |
|
| Trigger point injection with normal saline | Active Comparator | Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen |
|
| Trigger point injection with bupivacaine | Experimental | Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Trigger point injection with bupivacaine | Drug | Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed. |
| Measure | Description | Time Frame |
|---|---|---|
| Opioid consumption in the first 6 hour period after intervention (trigger point injection/sham) | Cumulative dose of opioid medications utilized in the time period. Measured in oral morphine equivalents. | 6 hours after intervention |
| Opioid consumption in the first 12 hour period after intervention (trigger point injection/sham) | Cumulative dose of opioid medications utilized in the time period. Measured in oral morphine equivalents. | 12 hours after intervention |
| Opioid consumption in the first 24 hour period after intervention (trigger point injection/sham) | Cumulative dose of opioid medications utilized in the time period. Measured in oral morphine equivalents. | 24 hours after intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Pain score at 6 hours after intervention (trigger point injection/sham) | Pain score will be assessed using visual analog scale. 0 indicates no pain and 10 indicates the worst possible pain. | 6 hours after intervention |
| Pain score at 12 hours after intervention (trigger point injection/sham) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| George Washington University Hospital | Recruiting | Washington D.C. | District of Columbia | 20037 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 11, 2025 | Mar 27, 2025 | 4 | ||
| Mar 28, 2025 |
| ID | Term |
|---|---|
| D005157 | Facial Pain |
| D019547 | Neck Pain |
| D001416 | Back Pain |
| D007714 | Klippel-Feil Syndrome |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D002045 | Bupivacaine |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Trigger point injection with normal saline | Drug | Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed. |
|
| Lidocaine skin wheal | Drug | Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection. |
|
Pain score will be assessed using visual analog scale. 0 indicates no pain and 10 indicates the worst possible pain. |
| 12 hours after intervention |
| Pain score at 24 hours after intervention (trigger point injection/sham) | Pain score will be assessed using visual analog scale. 0 indicates no pain and 10 indicates the worst possible pain. | 24 hours after intervention |
| Post-operative length of stay | Measured in days and hours | Through hospital discharge, an average of 2 days |
| Apr 11, 2025 |
| 5 |
| May 21, 2025 | May 21, 2025 | 6 |
| Aug 13, 2025 | Aug 14, 2025 | 7 |
| Sep 16, 2025 | Sep 16, 2025 | 8 |
| Dec 5, 2025 | Dec 8, 2025 | 9 |
| Mar 18, 2026 | Mar 18, 2026 | 10 |
| Jun 12, 2026 | Jun 12, 2026 | 11 |
| D004413 | Dysostoses |
| D001848 | Bone Diseases, Developmental |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D009139 | Musculoskeletal Abnormalities |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D000588 |
| Amines |
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |